Mepivacaine controlled release - Heron Therapeutics

Drug Profile

Mepivacaine controlled release - Heron Therapeutics

Alternative Names: APF112

Latest Information Update: 15 Jan 2014

Price : $50

At a glance

  • Originator A.P. Pharma
  • Developer Heron Therapeutics
  • Class Local anaesthetics; Piperidines; Small molecules
  • Mechanism of Action Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Suspended Postoperative pain

Most Recent Events

  • 13 Jan 2014 A.P. Pharma is now called Heron Therapeutics
  • 27 May 2008 Phase II development is ongoing
  • 12 Dec 2006 Mepivacaine controlled release is still available for partnering (http://www.appharma.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top